The unique neuropharmacology of such biased agonists may make them more suitable for therapeutic approaches, and future studies should determine if NLX-101 or other biased selective 5-HT1A receptor agonists are beneficial in children with FXS. This evidence concerns the gene HTR1A and fragile X syndrome.